Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alavert promotions

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare is partnering with Aetna to provide Alavert coupons, information on OTC loratadine to roughly 475,000 of Aetna's commercial members who have received an Rx for any non-sedating antihistamine in the past year, healthcare provider announces Feb. 5. Mailings are slated to begin in February and end in early April, firm says. Wyeth also has engaged in an Alavert marketing program with WellPoint (1"The Tan Sheet" Jan. 6, 2003, In Brief)...

You may also be interested in...

Aetna post-Claritin

Aetna's aggressive formulary management steps following OTC switch of Schering-Plough's Claritin have led to 80% decrease in members' use of Rx low- and non-sedating antihistamines, insurer says. After Claritin switched OTC, Aetna moved Schering's Clarinex, Aventis' Allegra, Pfizer's Zyrtec to "non-formulary" status, meaning members of open formulary plan can receive an Rx at the highest tier copay of $30-$35, resulting in no economic incentive for patients to choose Rx products. Aetna also partnered with Wyeth to include Alavert samples in mailings to physicians and members who received an Rx NSA in 2002 (1"The Tan Sheet" Feb. 10, 2002, In Brief). Managed care firm says it is developing a formulary strategy for PPIs following switch of Prilosec (2"The Tan Sheet" June 23, 2003, p. 3)...

WellPoint & Alavert

WellPoint Health Networks this month will mail three $10-off coupons for Wyeth's orally disintegrating loratadine to 438,000 members who received a prescription for a second-generation antihistamine within the past six months. Program marks WellPoint's first broad-scale couponing effort, although firm notes it has "dabbled" with coupons for OTC H2 antagonists in the past. WellPoint, which petitioned FDA to switch second-generation antihistamines OTC, says it approached Schering, Wyeth, McNeil about a cooperative marketing program for OTC loratadine and will split the couponing campaign's costs with Wyeth. In approving Alavert Dec. 23, FDA directed Wyeth to submit introductory promotional materials (1"The Tan Sheet" Dec. 23, 2002, p. 5). FDA says it also asked Schering to submit promotional materials for OTC Claritin; however, the request was made more informally and was not stated in the approval letters...

Execs On The Move: August 2023

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts